Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis After a First Demyelinating Event
NEJM 349:139-145,107, Berger,T.,et al, 2003
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1496-1504, Secondary Progressive Efficacy Clinical Trial of R, 2001
Oligoclonal Band Number as a Marker for Prognosis in Multiple Sclerosis
Arch Neurol 58:2044-2045, Avasarala,J.R.,et al, 2001
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
NEJM 339:285-291, 3391998., Confavreux,C.,et al, 1998
Life Expectancy in Patients Attending Multiple Sclerosis Clinics
Neurol 42:991-994, Sadovnick,A.D.,et al, 1992
Survival Pattern & Cause of Death in Patients with MS:Results From an Epidemiological Survey in North East Scotland
JNNP 50:523-531, Phadke,J.G., 1987
Multiple Sclerosis After Age 50
Neurol 33:1537-1544, Noseworthy,J.,et al, 1983
Mortality in Persons With Multiple Sclerosis in the Seattle & Los Angeles Areas
JAMA 246:2042-2045, Malmgren,R.M.,et al, 1981
The prognosis of Multiple Sclerosis
Editorial, BMJ 281:824-8251980., , 1980